文献速递自身炎症与 IgG4 相关病

泽布替尼单药治疗IgG4相关头颈部疾病的2期试验

Zanubrutinib monotherapy for IgG4-related head and neck disease.
PubMed 文献 · Ann Rheum Dis · 2026-07-14

这项2期开放标签概念验证试验纳入10例泪腺和下颌下腺IgG4相关病患者,接受泽布替尼80mg每日两次治疗24周,无糖皮质激素诱导。第24周腺体体积显著缩小,临床活动度和血清IgG4下降,不良事件以轻度为主。

要点

  • 泽布替尼单药治疗24周使泪腺体积平均缩小46.7%、下颌下腺缩小29.9%。
  • 临床活动度改善(IgG4-RD Responder Index下降6.0分),血清IgG4降低417mg/dL。
  • 不良事件以轻度为主,1例严重事件(COVID-19)发生在治疗外。

核心结论

  • 泽布替尼单药在活动性腺体IgG4相关病中产生显著的影像学和临床改善,且无需糖皮质激素诱导。

研究设计与样本

  • 2期开放标签概念验证试验,纳入10例泪腺和下颌下腺IgG4相关病患者,接受泽布替尼80mg每日两次治疗至24周,无糖皮质激素诱导或背景免疫抑制。

主要发现

  • 单细胞分析显示治疗调节B细胞转录程序、减少IgG4偏斜的浆母细胞并减弱细胞毒性CD4⁺T细胞。
  • 不良事件以轻度为主,1例严重事件(COVID-19)发生在治疗外。

临床怎么用

  • 泽布替尼单药可作为活动性腺体IgG4相关病的潜在免激素、非B细胞清除治疗策略。

局限性

  • 样本量小(10例),主要终点可评估仅8例,为开放标签概念验证试验,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immunoglobulin (Ig) G4-related disease (IgG4-RD) is commonly treated with glucocorticoids and B-cell depletion, but cumulative toxicity and relapse underscore the need for alternative approaches. We evaluated the efficacy, safety, and immunological effects of Bruton's tyrosine kinase (BTK) inhibition with zanubrutinib in active IgG4-RD. METHODS: In this phase 2, open-label, proof-of-concept trial, 10 participants with lacrimal and submandibular gland IgG4-RD received zanubrutinib 80 mg twice daily for up to 24 weeks without glucocorticoid induction or background immunosuppression. The primary endpoint was change in lacrimal and submandibular gland volume at week 24 by blinded fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (evaluable n = 8). Secondary endpoints included metabolic imaging parameters, clinical disease activity, serologic biomarkers, and safety. Single-cell RNA sequencing with immune repertoire profiling was performed to define cellular mechanisms. RESULTS: At week 24, mean gland volume decreased by 46.7% (lacrimal) and 29.9% (submandibular) (both P = .008), with concordant reductions in total lesion glycolysis (-91.6 g; P = .05) and total metabolic lesion volume (-20.7 cm³; P = .05). Clinical disease activity improved (IgG4-RD Responder Index -6.0 points; P = .01), alongside reductions in serum IgG4 (-417 mg/dL; P = .008) and circulating plasmablasts. Imaging and serologic changes were strongly correlated. Single-cell analyses demonstrated treatment-associated modulation of B-cell transcriptional programmes, reductions in IgG4-skewed plasmablasts, and attenuation of cytotoxic CD4⁺ T cells. Adverse events were predominantly mild; 1 serious event (COVID-19) occurred off treatment. CONCLUSIONS: Zanubrutinib monotherapy produced substantial imaging-defined and clinical improvements in active glandular IgG4-RD without glucocorticoid induction. BTK inhibition was associated with modulation of B-cell differentiation states and downstream immune programmes, supporting its development as a steroid-sparing, non-B-cell-depleting therapeutic strategy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Baker MC, Gawde S, Horomanski A, et al. Zanubrutinib monotherapy for IgG4-related head and neck disease. Ann Rheum Dis. 2026. PMID: 42448495. doi:10.1016/j.ard.2026.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。